PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A
Xiaohong Hu, Peijun Zhou, Xingzhi Peng, Yiting Ouyang, Dan Li, Xia Wu, Lifang Yang · 2024
Read PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A by Xiaohong Hu, Peijun Zhou, Xingzhi Peng, Yiting Ouyang, Dan Li, Xia Wu, Lifang Yang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11577825.txt.
Description
Glioblastoma, the most aggressive brain tumor, shrugs off radiation in many patients. Xiaohong Hu and six co-authors tested a drug called PXD101 against it in 2024, in cells and in animals. The drug loosens the packing of DNA, and it can cross from blood into brain, a step many drugs fail.
Treated tumor cells grew and invaded less, died more readily, and grew more sensitive to radiation. The drug worked by raising the level of a stress protein, GADD45A, which then switched on a death linked pathway. In animals, the drug paired with radiation slowed tumor growth clearly. The authors propose both the drug and the protein as leads for new care.
Catalog record
| CREATOR | Xiaohong Hu, Peijun Zhou, Xingzhi Peng, Yiting Ouyang, Dan Li, Xia Wu, Lifang Yang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |